Clinical Experiences With Momelotinib for Patients With Myelofibrosis

Dr Abdulraheem Yacoub discusses experience with the JAK inhibitor momelotinib in patients with myelofibrosis, noting robust efficacy in clinical trials for spleen volume reduction, symptom improvement, and anemia benefit, but explains that its utility in first-line versus second-line settings is still being determined.

EP: 1.Diagnosis and Risk Stratification of Myelofibrosis

EP: 2.Treatment Goals for Patients With Myelofibrosis

EP: 3.Currently Available Treatment Options for Patients With Myelofibrosis

Now Viewing

EP: 4.Clinical Experiences With Momelotinib for Patients With Myelofibrosis

EP: 5.Defining Severe Anemia in Patients With Myelofibrosis

EP: 6.Future of Myelofibrosis Treatment

Recent Videos